TABLE 1

Baseline characteristics of the study population (n = 116)

Sex
    Male47 (41)
    Female69 (59)
Age (years)76.8 ± 6.7
A1C level (%)*8.3 ± 1.2
BMI (kg/m2)28.3 ± 3.7
Creatinine level (μmol/l)§82.5 ± 14.4
Sulfonylurea use*
    Glibenclamide17 (14.7)
    Tolbutamide31 (26.7)
    Gliclazide7 (6.0)
    Glimepiride17 (14.7)
  • Data are means ± SD or n (%).

  • *

    * At the time of the last A1C measurement before start of metformin therapy.

  • At the time of entrance in the Rotterdam Study.

  • n = 114.

  • §

    § n = 88.